Tsukuba, Japan—Orexin, named after its role in feeding regulation, is a potent endogenous sleep/wake state regulator and is expected to play an essential role in controlling the cross-talk mechanism ...
Narcolepsy type 1 is a disorder of hypersomnolence caused by a loss of orexin neurons, which results in low orexin levels in the brain. In this phase 2, randomized, placebo-controlled trial, ...
An investigational oral selective orexin receptor 2 agonist (oveporexton, Takeda) demonstrated significantly improved measures of wakefulness, sleepiness, and cataplexy in a phase 2b study of adults ...
It’s not often that a pharmaceutical executive discusses a competitor’s success. Alkermes Chief Operating Officer Blair Jackson not only talks about it openly, he cheers it. Alkermes’s scope in ...
Vertex Pharmaceuticals Inc. has described orexin OX2 receptor agonists reported to be useful for the treatment of amyotrophic lateral sclerosis, obesity, hypertension, retinopathy, multiple sclerosis, ...
ZÜRICH, SWITZERLAND / ACCESSWIRE / December 3, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) (NLS), a biopharmaceutical company, is pleased to share preclinical data demonstrating the ...
– Takeda is the Leader in Orexin Science and is on Track to Submit Global Regulatory Applications Starting in Fiscal Year 2025 – Four Orexin Oral Presentations from Phase 3 Pivotal Studies Highlight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results